Suzanne B Merrill1, Stephen A Boorjian2, R Houston Thompson2, Sarah P Psutka3, John C Cheville4, Prabin Thapa5, Matthew K Tollefson2, Igor Frank6. 1. Division of Urology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. 2. Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. 3. Division of Urology, Hospital of Cook County, Chicago, IL, USA. 4. Department of Pathology, Mayo Clinic, Rochester, MN, USA. 5. Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA. 6. Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. frank.igor@mayo.edu.
Abstract
PURPOSE: To provide an alternative surveillance approach for bladder cancer (BC) following radical cystectomy (RC) according to more accurate predictions of a patient's projected BC course. METHODS: We identified 1797 patients who underwent RC for M0 BC between 1980 and 2007. Patients were stratified by pathologic stage (pT0Nx-0, pTa/CIS/1Nx-0, pT2Nx-0, pT3/4Nx-0, and pTanyN+), relapse location (urethra, upper tract, abdomen/pelvis, chest, and other), age (≤60, 61-70, 71-80, >80 years) and Charlson Co-morbidity Index (CCI ≤2 and CCI ≥3). Risks of disease recurrence and non-BC death were modeled using Weibull distributions. Recommended surveillance durations were estimated when the risk of non-BC death exceeded the risk of recurrence. RESULTS: At a median follow-up of 10.6 years (IQR 6.8,15.2), 713 patients developed recurrence. Vastly different recurrence patterns were appreciated. Specifically, among patients ≤60 years with pT2Nx-0, non-BC death risk exceeded the risk of recurrence in the abdomen at 7.5 years following surgery when CCI was ≥3, versus at year 10 after RC when CCI was ≤2. Meanwhile, for patients >80 years with pT2Nx-0, non-BC death risk exceeded the risk of abdominal recurrence at 1 year after RC, regardless of CCI. CONCLUSION: We present an alternative post-RC surveillance approach that incorporates a patient's changing risk profile with the influence of competing health factors. We believe this strategy provides more individualized recommendations than current guidelines, and may improve the benefit derived from surveillance while reducing resource misappropriation.
PURPOSE: To provide an alternative surveillance approach for bladder cancer (BC) following radical cystectomy (RC) according to more accurate predictions of a patient's projected BC course. METHODS: We identified 1797 patients who underwent RC for M0 BC between 1980 and 2007. Patients were stratified by pathologic stage (pT0Nx-0, pTa/CIS/1Nx-0, pT2Nx-0, pT3/4Nx-0, and pTanyN+), relapse location (urethra, upper tract, abdomen/pelvis, chest, and other), age (≤60, 61-70, 71-80, >80 years) and Charlson Co-morbidity Index (CCI ≤2 and CCI ≥3). Risks of disease recurrence and non-BC death were modeled using Weibull distributions. Recommended surveillance durations were estimated when the risk of non-BC death exceeded the risk of recurrence. RESULTS: At a median follow-up of 10.6 years (IQR 6.8,15.2), 713 patients developed recurrence. Vastly different recurrence patterns were appreciated. Specifically, among patients ≤60 years with pT2Nx-0, non-BC death risk exceeded the risk of recurrence in the abdomen at 7.5 years following surgery when CCI was ≥3, versus at year 10 after RC when CCI was ≤2. Meanwhile, for patients >80 years with pT2Nx-0, non-BC death risk exceeded the risk of abdominal recurrence at 1 year after RC, regardless of CCI. CONCLUSION: We present an alternative post-RC surveillance approach that incorporates a patient's changing risk profile with the influence of competing health factors. We believe this strategy provides more individualized recommendations than current guidelines, and may improve the benefit derived from surveillance while reducing resource misappropriation.
Authors: Suzanne B Stewart-Merrill; Stephen A Boorjian; Robert Houston Thompson; Sarah P Psutka; John C Cheville; Prabin Thapa; Eric J Bergstrahl; Matthew K Tollefson; Igor Frank Journal: Urol Oncol Date: 2015-05-29 Impact factor: 3.498
Authors: Stephen A Boorjian; Matthew K Tollefson; John C Cheville; Brian A Costello; Prabin Thapa; Igor Frank Journal: J Urol Date: 2011-09-25 Impact factor: 7.450
Authors: Gianluca Giannarini; Thomas M Kessler; Harriet C Thoeny; Daniel P Nguyen; Claudia Meissner; Urs E Studer Journal: Eur Urol Date: 2010-06-04 Impact factor: 20.096
Authors: Stephen A Boorjian; Simon P Kim; Matthew K Tollefson; Alonso Carrasco; John C Cheville; R Houston Thompson; Prabin Thapa; Igor Frank Journal: J Urol Date: 2013-01-09 Impact factor: 7.450
Authors: Guillaume Ploussard; Shahrokh F Shariat; Alice Dragomir; Luis A Kluth; Evanguelos Xylinas; Alexandra Masson-Lecomte; Malte Rieken; Michael Rink; Kazumasa Matsumoto; Eiji Kikuchi; Tobias Klatte; Stephen A Boorjian; Yair Lotan; Florian Roghmann; Adrian S Fairey; Yves Fradet; Peter C Black; Ricardo Rendon; Jonathan Izawa; Wassim Kassouf Journal: Eur Urol Date: 2013-10-09 Impact factor: 20.096
Authors: Christopher J D Wallis; James W F Catto; Antonio Finelli; Adam W Glaser; John L Gore; Stacy Loeb; Todd M Morgan; Alicia K Morgans; Nicolas Mottet; Richard Neal; Tim O'Brien; Anobel Y Odisho; Thomas Powles; Ted A Skolarus; Angela B Smith; Bernadett Szabados; Zachary Klaassen; Daniel E Spratt Journal: Eur Urol Date: 2020-09-04 Impact factor: 20.096